Avidity of Tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - Implications for vaccination strategies

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 6, 2006, Pages 701-706

  Ek, Torben ^a,b   Mellander, Lotta ^a   Hahn Zoric, Mirjana ^a   Abrahamsson, Jonas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Antibody; Avidity; Childhood acute lymphoblastic leukaemia; Haemophilus influenzae type b; Tetanus

Indexed keywords

ACT HIB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; TETANUS TOXOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOASSAY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELUTION; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; PRIORITY JOURNAL; REVACCINATION; SINGLE DRUG DOSE; TETANUS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; POLYSACCHARIDES, BACTERIAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TETANUS TOXOID;

EID: 33745064484     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250500459717     Document Type: Article

References (34)

1. Saarinen-Pihkala UM, Gustafsson G, Carlsen N, Flaegstad T, Forestier E, Glomstein A, et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer 2004;42:8-23.
2. Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151-61.
3. von der Hardt K, Jungert J, Beck JD, Heininger U. Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents - a retrospective analysis. Vaccine 2000;18:2999-3004.
4. Smith S, Schiffman G, Karayalcin G, Bonagura V. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster therapy. J Pediatr 1995;127:68-75.
5. Feldman S, Andrew M, Norris M, McIntyre B, Iyer R. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Clin Infect Dis 1998;27:388-90.
6. Nilsson A, De Milito A, Engstrom P, Nordin M, Narita M, Grillner L, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:e91.
7. Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004;101:635-41.
8. Brodtman DH, Rosenthal DW, Redner A, Lanzkowsky P, Bonagura VR. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005;146(5):654-61.
9. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive Treatment for Childhood Acute Lymphoblastic Leukemia Reduces Immune Responses to Diphtheria, Tetanus, and Haemophilus influenzae Type b. J Pediatr Hematol Oncol 2004;26:727-34.
10. Feldman S, Gigliotti F, Shenep JL, Roberson PK, Lott L. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990;161:926-31.
11. Heath PT, Booy R, Griffiths H, Clutterbuck E, Azzopardi HJ, Slack MP, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000;31:973-80.
12. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992;267:1489-94.
13. Breukels MA, Jol-van der Zijde E, van Tol MJ, Rijkers GT Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis 2002;34:191-7.
14. Mellander L, Bottiger M, Hanson LA, Taranger J, Carlsson B. Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr 1993;82:552-6.
15. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:1112-5.
16. Abrahamsson J, Carlsson B, Mellander L. Serum antibody levels and avidities to Escherichia coli O antigens and poliovirus type 1 antigen are increased in children treated for malignant disease. Med Pediatr Oncol 1999;32:416-20.
17. Galazka AM. The immunological basis for immunization series (3): Tetanus. Expanded programme on immunization. WHO Geneva 1993; 1993.
18. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
19. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001;20:63-75.
20. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:83-7.
21. Roberton DM, Carlsson B, Coffman K, Hahn-Zoric M, Jalil F, Jones C, et al. Avidity of IgA antibody to Escherichia coli polysaccharide and diphtheria toxin in breast milk from Swedish and Pakistani mothers. Scand J Immunol 1988;28:783-9.
22. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363-72.
23. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996;272:54-60.
24. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171(10):4969-73.
25. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-7.
26. Abrahamsson J, Mellander L. Bone marrow immunoglobulin-secreting cells are not reduced in children with leukaemia as compared to children with solid tumours. Acta Paediatr 1997;86:165-9.
27. Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, et al. The role of antibody concentration and avidity in antiviral protection. Science 1997;276:2024-7.
28. Fioredda F, Plebani A, Hanau G, Haupt R, Giacchino M, Barisone E, et al. Re-immunisation schedule in leukaemic children after intensive chemotherapy: a possible strategy. Eur J Haematol 2005;74:20-3.
29. Immunisation of the Immunocompromised Child Best Practice Statement. In: Royal College of Paediatrics and Child Health; 2002.
30. Graubner UB, Liese J, Belohradsky BH. [Vaccination]. Klin Padiatr 2001;213 Suppl 1:A77-83.
31. Schneerson R, Robbins JB. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med 1975;292:1093-6.
32. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202.
33. Stachel D, Futterer A, Haas RJ, Schmid I. Enhanced lymphocyte proliferation responses in pediatric patients early after myelosuppressive chemotherapy. Pediatr Blood Cancer 2004;43:644-50.
34. Nilsson A. Regulation of antibody production in immunocompromised patients. Stockholm: Karolinska Institutet; 2004.